A vasopressin prodrug that releases active peptide slowly for sustained vasoconstriction.
Also known as: Terlivaz · Glypressin
Part of the Foundational & therapeutic peptides cluster
Overview
Terlipressin is a synthetic analog of vasopressin built by adding three glycine residues to lysine-vasopressin. It acts as a slow-release prodrug, giving prolonged V1-mediated splanchnic vasoconstriction, and gained FDA approval in 2022 for hepatorenal syndrome. Content here is educational only.
Source & context
Biological / chemical source: Synthetic triglycyl-lysine analog of vasopressin
Primary research or clinical context: Approved for hepatorenal syndrome; used for variceal bleeding
Prodrug strategy
The triglycyl extension is cleaved gradually in the body to release lysine-vasopressin, converting a short-acting hormone into a sustained vasoconstrictor. This is a clear example of using a peptide prodrug to lengthen and smooth a drug's action.
Splanchnic vasoconstriction
By constricting splanchnic arteries, terlipressin lowers portal pressure, which underlies its use in hepatorenal syndrome and bleeding esophageal varices. It is a widely studied therapeutic peptide in hepatology and critical care.
FAQ about Terlipressin
What is Terlipressin?+
Terlipressin is a synthetic analog of vasopressin built by adding three glycine residues to lysine-vasopressin. It acts as a slow-release prodrug, giving prolonged V1-mediated splanchnic vasoconstriction, and gained FDA approval in 2022 for hepatorenal syndrome. Content here is educational only.
Is Terlipressin an approved medicine?+
Terlipressin: Approved for hepatorenal syndrome; used for variceal bleeding. Always follow licensed medical guidance for approved products.
What is the typical length of Terlipressin?+
Terlipressin is commonly described as approximately 12 amino acids (Vasopressin analog).